Literature DB >> 15596566

Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo.

Sui Zhang1, Dachun Wang, Zeev Estrov, Sean Raj, James T Willerson, Edward T H Yeh.   

Abstract

BACKGROUND: Adult human peripheral blood CD34-positive (CD34+) cells appear to transform into cardiomyocytes in the injured hearts of severe combined immunodeficient mice. It remains unclear, however, whether the apparent transformation is the result of transdifferentiation of the donor stem cells or of fusion of the donor cell with the cardiomyocyte of the recipients. METHODS AND
RESULTS: We performed flow cytometry analyses of cells isolated from the hearts of mice that received human CD34+ cells. Human HLA-ABC antigen and cardiac troponin T or Nkx2.5 were used as markers for cardiomyocytes derived from human CD34+ cells, and HLA-ABC and VE-cadherin were used to identify the transformed endothelial cells. The double-positive cells were collected and interphase fluorescence in situ hybridization was used to detect the expression of human and mouse X chromosomes in these cells. We found that 73.3% of nuclei derived from HLA+ and troponin T+ or Nkx2.5+ cardiomyocytes contain both human and mouse X chromosomes and 23.7% contain only human X chromosome. In contrast, the nuclei of HLA-, troponin T+ cells contain only mouse X chromosomes. Furthermore, 97.3% of endothelial cells derived from CD34+ cells contained human X chromosome only.
CONCLUSIONS: Thus, both cell fusion and transdifferentiation may account for the transformation of peripheral blood CD34+ cells into cardiomyocytes in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15596566     DOI: 10.1161/01.CIR.0000150796.18473.8E

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  55 in total

Review 1.  CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.

Authors:  Alexander R Mackie; Douglas W Losordo
Journal:  Tex Heart Inst J       Date:  2011

Review 2.  Getting to the heart of myocardial stem cells and cell therapy.

Authors:  Tara L Rasmussen; Ganesh Raveendran; Jianyi Zhang; Daniel J Garry
Journal:  Circulation       Date:  2011-04-26       Impact factor: 29.690

Review 3.  Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells.

Authors:  Sangho Lee; Young-Sup Yoon
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 4.  Stem cell treatment of the heart: a review of its current status on the brink of clinical experimentation.

Authors:  Paolo Angelini; Roger R Markwald
Journal:  Tex Heart Inst J       Date:  2005

5.  Adult progenitor cells for cardiac repair: preclinical studies.

Authors:  Edward T H Yeh
Journal:  Tex Heart Inst J       Date:  2009

Review 6.  Stem cells in the heart: what's the buzz all about? Part 2: Arrhythmic risks and clinical studies.

Authors:  Rachel Ruckdeschel Smith; Lucio Barile; Elisa Messina; Eduardo Marbán
Journal:  Heart Rhythm       Date:  2008-02-15       Impact factor: 6.343

Review 7.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 8.  Engineering Functional Cardiac Tissues for Regenerative Medicine Applications.

Authors:  Martin L Tomov; Carmen J Gil; Alexander Cetnar; Andrea S Theus; Bryanna J Lima; Joy E Nish; Holly D Bauser-Heaton; Vahid Serpooshan
Journal:  Curr Cardiol Rep       Date:  2019-08-01       Impact factor: 2.931

Review 9.  Challenges in cardiac tissue engineering.

Authors:  Gordana Vunjak-Novakovic; Nina Tandon; Amandine Godier; Robert Maidhof; Anna Marsano; Timothy P Martens; Milica Radisic
Journal:  Tissue Eng Part B Rev       Date:  2010-04       Impact factor: 6.389

10.  Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.

Authors:  Michalis Mastri; Zaeem Shah; Terence McLaughlin; Christopher J Greene; Leah Baum; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Cell Physiol       Date:  2012-07-25       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.